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T cell priming is a critical event in the initiation of the immune response to vaccination since
it deeply influences both the magnitude and the quality of the immune response induced.
CD4+ T cell priming, required for the induction of high-affinity antibodies and immune
memory, represents a key target for improving and modulating vaccine immunogenicity.
A major challenge in the study of in vivo T cell priming is due to the low frequency of
antigen-specific T cells. This review discusses the current knowledge on antigen-specific
CD4+T cell priming in the context of vaccination, as well as the most advanced tools for the
characterization of the in vivoT cell priming and the opportunities offered by the application
of systems biology.
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INTRODUCTION
T cell priming is an essential event for the induction of the adap-
tive immune response to vaccination. T cell priming is influenced
by the type of vaccine formulation (antigen, adjuvant, delivery
system), the dose and the route of administration. The charac-
terization of T cell priming induced by a vaccination strategy is
therefore critical in order to develop optimal prime-boost combi-
nations capable of eliciting the type of immune response required
to fight a specific pathogen.
The efficacy of most preventive vaccines relies on antibody
response to block pathogen infection and generation of immune
memory cells capable of rapid and effective reactivation following
pathogen re-exposure (1, 2). In this context, primary activation of
T-helper cells that are required for the induction of high-affinity
antibodies and immune memory is essential (2). Furthermore,
CD4+ T cell priming has been shown to be an early predictor of
vaccine immunogenicity in humans (3, 4).
A limitation in the study of in vivo T cell priming is due to the
low frequency of antigen-specific T cells. This has been overcome
by the application of technologies such as adoptive transfer of
transgenic antigen-specific T cells into recipient mice and major
histocompatibility complexes (MHCs) class II tetramers (5, 6). It is
particularly attractive to also consider systems biology approaches
that have been recently applied to vaccinology to model T cell
priming and develop tools to predict vaccine responsiveness and
efficacy (7–9).
Here we review the current knowledge on antigen-specific
CD4+ T cell priming in the context of prophylactic vaccination.
Immunological events following primary vaccination by systemic
and mucosal routes and their relevance for the rational devel-
opment of prime-boost strategies are addressed. Moreover, the
methodologies for studying in vivo CD4+ T cell priming and
the potential of applying systems biology for its modeling are
discussed.
IMMUNE MECHANISMS OF CD4+ T CELL PRIMING
CD4+ T cell priming represents a key step in the vaccination
process due to the close relationship between CD4+ T cells and
both long-term humoral immunity and protective antibodies.
CD4+ T cell priming is influenced by several factors such as the
local pro-inflammatory environment, the nature and the dose of
the antigen, the vaccine formulation including the type of adjuvant
and the route of immunization (10, 11). A schematic representa-
tion of the T cell priming event in the context of vaccination is
reported in Figure 1. Generation of primed T-helper cells requires
contact between antigen-bearing dendritic cells (DCs) and specific
CD4+ T cells within the T zone of the lymph node (LN) closest to
the site of vaccination (2, 12). The process of CD4+ T cell priming
begins when naïve cells, that constantly transit between the circu-
latory and lymphatic systems, bind their T cell antigen receptors
(TCRs) to foreign peptides loaded on MHCs class II molecules pre-
sented by antigen presenting cells (APCs), thus leading to T cell
proliferation (13). Antigen persistence and duration of peptide
presentation by APCs influence the magnitude of the primary T
cell response (14, 15). The very early interaction between antigen-
specific T cells and peptide-MHC-bearing APCs within the LN
has been described with static and dynamic imaging methods and
movies (13,16,17). Interaction between APCs and antigen-specific
naïve T cells takes place within the first 8–20 h and is dependent
on the presence of the antigen (13). Activated T cells begin to pro-
liferate and finally, in a later and antigen-independent phase, they
expand and differentiate into various functionally defined subsets
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FIGURE 1 | Immune response triggered by vaccination. Primary immune
response triggered by vaccine administration is influenced by several factors,
such as the vaccine formulation (including delivery systems and/or adjuvants),
the nature and the dose of the antigen, and the route of immunization.
(A) After vaccine administration, DCs mature and migrate to the T cell zone of
draining LNs. DCs express vaccine epitopes on their MHC class II molecules,
thus engaging naïve antigen-specific CD4+ T cells and inducing their
proliferation and differentiation into effector T-helper cells (1). The local
environment deeply influences the T cell priming event and the polarization of
distinct effector T cell subsets (2). Effector T cells differentiate into
subpopulations, such as Th1, Th2, Th17, Treg that mainly exert their function
outside the LN. Some primed CD4+ T cells differentiate into Tfh that relocate
to B-T cell borders. Cognate contact between Tfh cells and antigen-primed B
cells in the extra-follicular regions of the lymph nodes is required for clonal
expansion and antibody class switching (without affinity maturation) of
short-lived plasma cells. GC-Tfh drives the GC reaction, in which B cells
undergo clonal expansion, isotype switching, affinity maturation, and
differentiate into long-lived plasma cells. (B) Low-affinity IgM and IgG
antibodies produced by short-lived plasma cells during the extra-follicular
reaction, appear at low levels in the serum within a few days after
immunization (3). Effector Th1, Th2, and Th17 subpopulations exit the LN and
through the blood disseminate toward other LNs and toward the inflamed
tissue (in this context, the site of vaccine inoculation) where exert their
effector function (4). (C) The long-lived plasma cells exit the LN at the end of
the GC reaction and migrate to survival niches mostly located in the bone
marrow (BM) where they survive through signals provided by supporting
stromal cells and continue to release hypermutated antibodies (5). Another
fraction of B cells, matured during the GC reaction, develop a memory
phenotype and disseminate into the extra-follicular areas of the LN where
they persist as resting cells until booster immunization or pathogen encounter
(6). Memory T cells traffic through T cell areas of secondary LNs and BM
(Tcm) (6), or localize within tissue (Tem) (7). Booster immunization induces a
rapid reactivation of memory B and T cells, with proliferation and
differentiation into effector cells. Memory B cells mature into plasma cells
secreting large amounts of high-affinity antibodies that may be detected in
serum within a few days after boosting.
of effector cells that, depending on the nature of the cytokine
milieu generated by innate cells, express specific master transcrip-
tion factors (18, 19). Polarization of the distinct effector T cell
subsets is indeed regulated by the strength of antigenic stimula-
tion, as well as by the cytokines present during priming (20). These
polarizing cytokines are derived from the APCs, the responding T
cells or bystander cells. Effector T cells can be emigrant lympho-
cytes such as Th1, Th2, or Th17 that exit the LNs and move to
inflamed tissues, regulatory cells (Treg), or T follicular helper (Tfh)
cells that relocate to B-T cell borders and interfollicular regions
(21–23). Tfh cells are specialized to regulate multiple stages of
antigen-specific B cell immunity through cognate cell contact and
the secretion of cytokines (21). In the extra-follicular reaction,
some antigen-primed B cells, after cognate contact of Tfh cells,
undergo a process of rapid differentiation in short-lived plasma
cells producing low-affinity antibodies such as IgM and IgG that
appear in serum at low concentration a few days after immu-
nization (2, 21). Interaction of Tfh cells with B cells drives the
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formation of germinal center (GC) a dynamic micro-anatomical
structure that supports the generation of B cell activation,antibody
class switch recombination and affinity maturation (22, 24). Tfh
cells that localize in GCs are referred to as GC-Tfh cells. A fraction
of B cells matured during the GC reaction acquires the capacity
to migrate toward long-term survival niches located within the
bone marrow (BM) from where they can release vaccine antibod-
ies for extended periods. Another fraction includes class-specific
affinity-matured memory B cells that are able to rapidly expand
and differentiate into plasma cells after antigen re-challenge (25).
Upon primary activation most of the antigen-experienced
CD4+ T cells are short-lived and undergo apoptotic contraction
leaving only a small fraction of competent memory precursor cells
to migrate into the BM where they differentiate into long-lived
memory cells. The frequency of memory T cells reflects therefore
the magnitude of the initial T cell expansion and of its subsequent
contraction. Two types of memory T cells have been identified
based on their phenotype and function (26). Effector memory T
cells (Tem) are circulating or tissue-resident cells and exert their
immediate effector function after antigen encounter and mediate
site-specific protection, while central memory T cells (Tcm) pref-
erentially traffic through T cell areas of secondary LNs and BM
and have a high proliferative potential (26). Their role is to recog-
nize antigens transported by activated DCs into LNs and to rapidly
undergo massive proliferation generating a delayed, but very large,
wave of effector cells (26, 27). During a primary response mem-
ory Tfh cells are also generated. These cells are retained within
draining lymphoid sites together with antigen-specific memory B
cells and persistent complexes of peptide-MHC II (28). During
a booster immunization, vaccine antigens restimulate memory T
and B cells that rapidly activate a secondary immune response.
CD4+ T CELL PRIMING IN VACCINATION
In the context of vaccination strategies, T cell priming can be
evaluated as a target for improving the immune response dur-
ing vaccination as well as a tool for modulating the quality of
the immune response. The nature and the dose of the vaccine
antigen, the adjuvant or the vaccine delivery used, the route of
immunization and the local environment are all factors that deeply
affect the primary activation of CD4+ T cells (10, 11).
The development of distinct effector CD4+ T cell subsets is
determined to a great extent by cytokines present during the T
cell priming event that act as powerful polarizing factors (10).
APCs express toll-like receptors (TLRs) that recognize distinct and
highly conserved pathogen-associated molecules, thus activating
a signaling cascade that dramatically impacts the quality and the
quantity of the T cell response. This has encouraged the use of
TLRs ligands as promising adjuvants (10, 29–33), that can influ-
ence the effector fate of antigen-specific primed CD4+ T cells (10).
CD4+ T cell priming has been studied for characterizing the mech-
anism of action of adjuvants such as alum (34), the CpG ODN (35),
the lipopolysaccharide (36) or its derivative-like monophosphoryl
lipid A (37), cholera toxin (38), or its B subunit (CTB) (39, 40).
Another aspect to consider is the selection of the route of
administration of the vaccine that affects the quality and the local-
ization of the T cell response (41, 42). CD4+ T cell priming
following immunization by different mucosal routes has been
characterized in the murine model (35, 38, 43–45) as discussed
in the next section. Recently, we have also demonstrated that the
route used for priming, but not for booster immunization, influ-
ences the skewing of the CD4+ T effector response toward Th1 or
Th2 with a stronger Th1 polarization upon nasal administration
compared to the systemic one (46).
The development of vaccination approaches aimed at enhanc-
ing Tfh primary response is particularly attractive. The interaction
of T-B cells is stabilized by adhesion molecules, such as the signal-
ing lymphocytic activation molecule (SLAM) family, that initiate
intracellular signaling via recruitment of specific adapters such as
the SLAM/associated protein (SAP) family (47). Targeted manip-
ulation of the SAP/SLAM family has been employed recently
as strategy for shaping and strengthening the immune response
during vaccination (47, 48). The employment of a nanoparticle
delivery system has also recently been shown to promote robust GC
formation and enhance the expansion of vaccine antigen-specific
Tfh cells leading to an enhanced humoral response (49).
The role of CD4+ T cells in developing durable functional neu-
tralizing antibody responses, via Tfh cells, is considered of key
importance for the development of vaccines against pathogens
for which no vaccine is currently available, such as HIV (50).
Despite the central role of T-helper cells in vaccine immunity, the
specific contribution of HIV-specific CD4+ T cells in HIV infec-
tion is largely unknown and these cells have mostly been excluded
from HIV vaccine design strategies because they can be infected by
the virus itself (50). Strikingly, in simian immunodeficiency virus
(SIV)-infected non-human primates, Tfh cells did not seem to be
preferentially infected by the virus, and their frequency in LNs
correlated with the magnitude of the SIV-specific IgG response,
the avidity of the SIV-specific antibodies and the generation of the
GCs (51).
Studies of H5N1 influenza vaccination of healthy adults have
shown an increase in the frequency of virus-specific CD4+ T
cells measured 22 days after the first dose. This increase predicted
a rise in neutralizing antibody concentrations after boosting as
well as their maintenance 6 months later (3, 52), thus suggesting
that primary CD4+ T cell response can be considered a predictor
marker of the secondary immune response. Similarly, CD4+ T cell
expansion has shown to predict neutralizing antibody response to
monovalent inactivated influenza A H1N1 vaccine (4).
MUCOSAL CD4+ T CELL PRIMING
Targeting mucosal sites by vaccination is an important goal con-
sidering that over 90% of infections occur at or through mucosal
surfaces. The induction of mucosal immune responses requires the
presence of a mucosa-associated lymphoid tissue that provides
a continuous source of B and T cells to mucosal effector sites
(53). A schematic representation of T cell priming in differ-
ent mucosal sites following mucosal vaccination is reported in
Figure 2. Inductive sites for mucosal immunity consist of orga-
nized mucosa-associated lymphoid tissue as well as local and
regional draining LNs, whereas the effector sites include different
compartments mainly consisting of the lamina propria of various
mucose (54). Inductive sites in the gastro-intestinal and respira-
tory tracts have been well defined, and are composed by aggregated
lymphoid tissues (gut-, nasal-, and bronchial-associated lymphoid
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tissues, respectively) and mucosa-associated LNs (mesenteric and
mediastinal LNs). On the contrary, the vaginal mucosa is devoid
of histologically demonstrable organized mucosa-associated lym-
phoid tissue and the role of inductive site is played directly by
draining iliac LNs (55). Moreover, antigen-uptake across the vagi-
nal mucosa barrier and immune responses in the genital tract are
greatly regulated and influenced by the hormonal state and estrus
phase (56). Female genital tract has therefore some unique fea-
tures that should be taken in consideration in the development of
a vaccination strategy.
By using the adoptive transfer system (described in the next
section), our laboratory has deeply analyzed the CD4+ T cell prim-
ing following nasal and vaginal immunization in the mouse model.
Intranasal immunization with the recombinant vaccine vector
Streptococcus gordonii (57–62), elicited an early clonal expansion of
antigen-specific CD4+ T cells in the nasal-associated lymphoid tis-
sue (NALT), and cervical and mediastinal LNs 3 days after immu-
nization (43–45). Proliferated T cells were CD44hiCD45RBlo and
expressed CD69 molecule within the early cell generations (44).
Divided T cells disseminated in the respiratory (44), genital,
and intestinal tracts (43) where they become detectable 5 days
after priming. Similar results of antigen-specific clonal expan-
sion and dissemination were observed immunizing with soluble
ovalbumin (OVA) plus the adjuvant CpG ODN (35, 46). We also
demonstrated that homing of nasally primed T cells into distal
peripheral LNs was CD62L-dependent, while entry into mesen-
teric LNs depended on both CD62L and α4β7 expression (35)
(Figure 2).
T cell priming was also studied following vaginal immunization
in hormone synchronized mice, showing a very efficient activa-
tion of CD4+ T cells (38, 63). Antigen-specific CD4+ T cell clonal
expansion was indeed detected in iliac LNs, and proliferated T
cells disseminated toward distal LNs and spleen, similarly to what
observed following nasal immunization (38). These data show
that vaginal immunization is efficient in eliciting CD4+ T priming
despite the absence of an organized mucosa-associated inductive
site in the genital tract (Figure 2).
PRIME-BOOST APPROACH
Characterization of the magnitude and quality of the T cell prim-
ing elicited by a vaccine formulation is critically important for
the rational development of prime-boost vaccine combinations.
An interesting approach to vaccination is indeed the heterologous
prime-boost strategy that primes the immune system to a target
antigen delivered by a vector and then selectively boosts the sec-
ondary response only to the vaccine antigen by using a different
FIGURE 2 |T cell priming in different mucosal sites following mucosal
vaccination. Mucosal vaccination targets the epithelium that covers
mucosal surfaces. (A) In many mucosal sites, such as the gastro-intestinal
and respiratory tracts, underneath the epithelium barrier inductive sites are
present, constituted by organized lymphoid tissue. Following vaccination,
antigen is sampled by local DCs and transported into the inductive site
where antigen-specific T cell priming occurs. Activated T cells migrate from
the inductive site toward the regional draining LNs and then enter into the
circulatory torrent through the lymphatic system. (B) Vaginal mucosa is
devoid of histologically demonstrable organized mucosa-associated
lymphoid tissue, therefore after immunization, the antigen is sampled by
tissue-resident DCs and transported into the draining iliac LNs that
constitute the inductive site. Primed T cells exit the LNs and migrate
through the lymphatic system into the blood. (C) A fraction of mucosally
primed T cells transiently circulates through the blood into the spleen and
disseminates into non-draining LNs; the entry into peripheral LNs is
CD62L-dependent, while into mesenteric LNs depends on both CD62L and
α4β7 expression.
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vaccine formulation. The heterologous prime-boost approach is
specifically aimed at the generation and enrichment of high avidity
T cells specific for the target antigen (64). Boosting with a differ-
ent vector carrying the same antigen has been shown to be more
efficient in inducing the immune responses compared to boosting
with the same vector. The heterologous prime-boost approach is
currently exploited in human studies aimed at developing vaccines
against pathogens such as HIV (65), tuberculosis (66), and malaria
(67). Furthermore, mucosal and parenteral routes can be com-
bined in a vaccination prime-boost strategy to induce immune
responses in both the local and systemic compartments. This
approach has shown to be as strong or stronger than those resulting
from homologous mucosal or parenteral vaccination alone (68–
71). Recently, we have demonstrated that the polarization of CD4+
T effector cells is affected by the route used for priming but not
for boosting, while local effector responses are mainly dependent
on booster route (46).
Recent studies in the mouse model have also assessed the role of
peptide-based priming on the subsequent B cell response elicited
by whole protein boosting (72) or by infection with the pathogen
(73) or with an attenuated viral vaccine (74). These studies showed
that CD4+ T cell help is quite selective for the subsequent anti-
body production. CD4+ T cells specific for an epitope provide the
appropriate help mainly to the protein-specific B cells, indicat-
ing a deterministic linkage between antibodies and CD4+ T cell
responses (73, 74), even if discordant results have been recently
reported (75).
Understanding the priming mechanisms of a vaccine formula-
tion and optimizing its priming properties is therefore of critical
relevance for the informed design of next generation prime-boost
strategies.
TOOLS TO STUDY T CELL PRIMING
Antigen-specific primary activation has been mostly analyzed in
animal models, within LNs draining the inoculation site or in the
spleen. Primed CD4+ T cells can be detected in draining LNs
within a few days after immunization, with a peak after 5–7 days
(13, 43, 76). In humans, primed T cells can be studied in peripheral
blood starting from 7 days following vaccination (4).
Several procedures have been employed to characterize antigen-
specific primed T cells, including assays of helper cell activity using
carrier/hapten systems (77), and the commonly used proliferation
and cytokine production assays. These methods measure func-
tional parameters as a read-out for T cells which react to the specific
antigen challenge in vitro. A major limitation of these assays is that
the phenotypic and functional properties of the reactive cells may
be altered by the in vitro antigenic restimulation (78).
To overcome this limitation, technologies such as the adoptive
transfer of TCR-transgenic T cells in mice (79) and, more recently,
MHC class II tetramers (6) have been developed to allow the ex
vivo analysis of primed T cells (see below). A summary of the most
used assays for studying T cell priming in human and animal stud-
ies, with their main advantages and disadvantages, is reported in
Table 1.
ADOPTIVE TRANSFER OF TRANSGENIC ANTIGEN-SPECIFIC T CELLS
In order to overcome the limitation of the low frequency of
antigen-specific T cells in vivo, Jenkins and colleagues developed
the adoptive transfer model of antigen-specific transgenic T cells
into recipient mice (79). This system largely increases the num-
ber of antigen-specific naïve CD4+ T cells in vivo by employing
TCR-transgenic mice that express a TCR specific for a defined
peptide/MHC complex on most T cells, and thus allows the
ex vivo analysis of their clonal expansion following antigenic
stimulation (5). In order to track their proliferation, trans-
genic T lymphocytes are labeled with the vital dye 5-(and -
6)-carboxyfluorescein diacetate succinimidyl ester (CFSE) (80)
and then injected intravenously into immunocompetent recipi-
ent mice. Following vaccine administration, the T cell prolifer-
ation in the secondary lymphoid organs can be studied by flow
cytometric analysis of CFSE dilution in the single-cell genera-
tions. The adoptive transfer method has proven to be a pow-
erful tool for studying T cell primary responses to parenteral
and mucosal immunization (35, 38–40, 43–45, 81–86), the role
of the microenvironment for initiating T cell response in sec-
ondary lymphoid tissues (87) and the impact of aging on cellular
immunity (88). Transgenic mice extensively used for studying
the development of CD4+ T cell primary activation following
immunization include DO11.10 (89) and OT-II (90) strains that
contain rearranged TCR-Vα and -Vβ genes in the germline DNA
encoding a TCR specific for chicken OVA peptide323–339 bound to
I-A molecules in a context of H-2d and H-2b haplotype, respec-
tively. Other transgenic models have been developed, such as
SM1 RAG-2 deficient mice, that allow the visualization of Sal-
monella flagellin-specific CD4+ T cell responses (91), SMARTA
transgenic mice, that produce CD4+ T cells expressing Va2 and
Vb8.3 TCR specific for the lymphocytic choriomeningitis virus
(LCMV) epitope gp61–80 (92), and Ag85B241–255 TCR-transgenic
mice that allow to characterize tuberculosis-specific immune
response (86).
Despite the important results obtained with this system, it has
the limitation that the high number of naïve antigen-specific T
cells transferred into recipient mice alters the physiologic condi-
tions and can influence the immune response observed. Moreover,
the study of the antigen-specific primary response is limited by the
availability of the transgenic mouse strains with the TCR specific
for a given model antigen.
MHC CLASS II TETRAMERS
The limitations of the methodology described above have been
overcome with the development of MHC-peptide complexes. In
1996, the first work describing the use of a peptide-MHC class
I complex for the identification and characterization of antigen-
specific T lymphocytes was published (93). Initially developed for
the study of CD8+ T cells, the technology has been extended to
the class II system in the context of CD4+ T cells (6, 94) and
has been applied to the study of human and murine T cells (95–
97). This tool has provided an invaluable way to monitor T cell
mediated immune responses and quantify the development of an
antigen-dependent response. The technology allows identification
of antigen-specific T cells based on the specificity of their surface
TCR for particular MHC-peptide complexes. Since the affinity
of TCR for a single peptide-loaded MHC molecule is generally
low, multimerization of the peptide-MHC complexes is neces-
sary for achieving much higher avidities for the TCR (93, 97).
Today, the most prevalent multimer used consists of biotin-labeled
www.frontiersin.org December 2013 | Volume 4 | Article 421 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ciabattini et al. CD4+ T cell priming upon vaccination
Table 1 | Methods used for studying antigen-specificT cell priming in humans and animals.
Analysis Assay Cellular
function
Technical
methodology
Advantages Disadvantages
In vitro Proliferation Cell
proliferation
3HTdR
incorporation
Wide response not restricted to single
epitope; high sensitivity
Restimulation and expansion in vitro; use
of radioisotopes
Limiting dilution
assay
Detection of rare specific T cells Restimulation and expansion in vitro; use
of radioisotopes; labor intensive
Colorimetric
assays
No use of radioisotopes Restimulation and expansion in vitro; low
sensitivity
Cytokine
release
Cytokine
secretion
ELISPOT Selective identification of distinct cytokine
producing cell subsets
Restimulation; identifies only cytokine
secreting cells; no phenotypic
characterization
FACS staining Phenotypic analysis Restimulation; identifies only cytokine
secreting cells; low sensitivity, lethal cell
fixation
Ex vivo Adoptive
transfera
Cell
proliferation
FACS staining No restimulation; phenotypic analysis of cell
generations; localization of labeled cells
Few transgenic mouse strains available;
altered physiological condition; laborious
procedure
MHC II
tetramers
Enumeration
of Ag-specific
cells
FACS staining No restimulation; analysis in physiological
condition; phenotypic analysis; rapid analysis;
independent from T cell function; high
specificity
Peptides have to be predefined;
complicated manufacturing; restricted to
single epitope specificities
aOnly in mice.
peptide-MHC complexes bound to streptavidin molecules form-
ing tetravalent structures (96). The peptide of interest can be
covalently linked to the β-chain of the MHC molecule for the
generation of MHC molecule-peptide complexes or it can be
loaded on empty soluble class II molecules (95). Tetramer tech-
nology offers the advantage of phenotyping the antigen-specific
cells by combining surface marker labeling and allows for the
simultaneous detection of different antigen-specific CD4+ T cells
by using multiple tetramers conjugated to different fluorescent
molecules. The major limitations in the use of tetramers are
that immunodominant peptides have to be predefined and that
humans have very diverse HLA class II molecules. Moreover, the
low frequency of antigen-specific CD4+ T cells in blood (gen-
erally 1/3000–30000) and the low avidity of TCR-MHC-peptide
complex recognition are challenging issues for the tetramer tech-
nology. One strategy developed to overcome the first problem is
the selection of the tetramer-positive cells by sorting with mag-
netic beads, so the antigen-specific population could be enriched
as much as 10,000-fold (76, 98).
By using distinct MHC class II tetramers, Jenkins and colleagues
have analyzed in the mouse model the primary response of CD4+
T cells specific for three different peptides [the protein FliC427–441
of Salmonella typhimurium, the OVA323–339, and the 2W1S variant
of I-Eα protein52–68 (2W)] following intravenous immunization
and correlated the primary response to the frequency of the respec-
tive naïve population size by combining the tetramer staining to
the magnetic bead enrichment (76). Since the frequency of the
naïve pool of 2W-specific CD4+ T cells in C57BL/6 mice, was
the highest among the three peptides assessed, this peptide has
been selected for its expression on Listeria monocytogenes and
Leishmania major in order to track, by mean of the 2W-MHC
class II tetramer, the peptide-specific T cell primary response fol-
lowing acute infection (99, 100). MHC class II tetramers have been
used for identifying CD4+ T cell epitopes of Porphyromonas gin-
givalis proteins following oral infection of mice and as a tool for
tracking and phenotyping specific effector and memory CD4+ T
cells (101). In other murine studies, the magnitude and quality
of the CD4+ T cell response induced by oral immunization with
lipid-formulated BCG has been analyzed by using Mycobacterium
tuberculosis Ag85B280–294-specific MHC class II tetramers, and
compared with that induced by the subcutaneous immunization
with BCG (102).
SYSTEMS BIOLOGY APPROACH FOR STUDYING T CELL PRIMING
Mathematical and computational modeling can be employed as
tool for integrating experimental data into a quantitative analysis
of immune responses to antigens. Application of systems biology
in vaccinology, named systems vaccinology, has recently been pro-
posed as new powerful tool to model and characterize immune
responses to vaccination and to predict vaccine immunogenic-
ity and efficacy (8, 9). Systems vaccinology aims to model the
immunological network, from molecules to cells to tissues, in
order to predict vaccine immunogenicity. The identification of
molecular signatures induced early after vaccination which corre-
late with and predict the later development of protective immune
responses, represents a strategy to prospectively determine vac-
cine efficacy. Systems biology approaches provide a detailed level
of investigation to better and fully analyze the network of inter-
actions within vaccine-specific innate and adaptive immunity. All
this information is expected to high impact on rational vaccine
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development, providing molecular prediction markers of vaccine
immunogenicity, uncovering new correlates of vaccine efficacy,
as well as guiding the design of new vaccine formulations and
prime-boost strategies (7).
Systems biology represents therefore an attractive tool for
studying T cell priming and modeling the initiation of the immune
response following vaccination and predicting the priming prop-
erties of different vaccine formulations. The application of math-
ematical models can indeed be highly relevant to analyze antigen-
specific T cell primary clonal expansion, based on the dilution of
the CFSE dye. Quantitative analysis of T cell proliferation through
mathematical models has been previously employed for in vitro
studies of lymphocyte proliferation (103–105). On the contrary,
the application to in vivo analysis raises several difficulties, mainly
due to the fact that a LN is not an “isolated” site but is part of the
complex immunological system.
Our group has recently employed a Multi-type Galton–Watson
branching process with immigration (63, 106) to model in vivo
CD4+ T cell priming and estimate the probabilities of a cell to
enter in division, rest in quiescence or migrate/dye. This model has
been successfully applied to analyze CD4+ T cell priming in mice
immunized by different mucosal routes, such as vaginal or nasal,
and has allowed the estimation of the probability of CD4+ T cells
to enter into division within the draining LNs (63). Ongoing work
is focused on modeling lymphocyte trafficking within the lym-
phatic systems, including both draining and distal LNs and spleen,
in order to obtain further quantitative information and generate
a model capable of predicting the amount and distribution of
primed CD4+ T cells.
CONCLUDING REMARKS
CD4+ T cell priming is an early biomarker of vaccine immuno-
genicity that should be considered as a critical parameter in the
evaluation of vaccination strategies. The advances in understand-
ing CD4+ T cell priming and the availability of latest generation
technologies for its study open the way for its use in the rational
design of vaccine formulations and prime-boost combinations.
CD4+ T cell priming can be also considered an important bio-
marker for early prediction of vaccine immunogenicity and indi-
vidual responsiveness to vaccination. The application of systems
biology and mathematical modeling to the study of CD4+ T cell
priming offers further opportunities to identify early signatures of
vaccine immunogenicity and guide the design of next generation
vaccines.
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